Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 210 of 370
Next
>>
>
5226 to 5250 of 9248 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Antibody	Perturbagen Target	Perturbagen Class	Biological Replicate ID	Conc Unit	GR50	GEC50	GRmax	GRinf	GR Hill Coefficient	GR_AOC	GR r2	Nominal Division Rate
MCF12A	NM	Basal B	PD184352		MEK	MAPK	12365.155	uM	15.39130	54.87560	0.1876	-1.0000	0.8642	0.1264	0.9279	2.1113
MCF12A	NM	Basal B	PD184352		MEK	MAPK	12365.155	uM	15.39130	54.87560	0.1876	-1.0000	0.8642	0.1264	0.9279	2.1113
MCF12A	NM	Basal B	Pemetrexed		TYMS/DHFR/GARFT	TYMS	7490.095	uM	0.51685	0.13152	0.4471	0.4617	1.8764	0.4189	0.9963	2.7242
MCF12A	NM	Basal B		Pertuzumab			7489.102	mg/ml	inf	125.00000	0.8728	0.5007	0.2455	0.0447	0.7417	2.4234
MCF12A	NM	Basal B	PS-1145		IKK	NFKB	7490.065	uM	inf	inf	0.9204	0.9204	0.0000	-0.0153	0.3912	2.4816
MCF12A	NM	Basal B	Purvalanol A		CDK1	CDK	7490.067	uM	inf	inf	0.9463	0.9463	0.0000	0.0115	0.2333	2.6472
MCF12A	NM	Basal B	Purvalanol A		CDK1	CDK	7489.067	uM	27.37850	27.41970	-0.0035	-0.0038	5.0000	0.1228	0.990	1.7603
MCF12A	NM	Basal B	QNZ		NFkB	NFKB	7490.096	uM	inf	0.11413	0.7216	0.7477	1.7461	0.1198	0.9390	2.5767
MCF12A	NM	Basal B	Ribavirin				15354.211	uM	inf	inf	0.7146	0.7146	0.0000	0.0912	0.5457	2.0320
MCF12A	NM	Basal B	SB-3CT		MMP2/9	MMP	12365.168	uM	inf	inf	0.9495	0.9495	0.0000	0.0418	0.0004	2.1914
MCF12A	NM	Basal B	SB-3CT		MMP2/9	MMP	10817.144	uM	inf	10.66090	0.9205	0.9198	4.9870	0.0113	0.6311	1.4640
MCF12A	NM	Basal B	Selumetinib		MEK	MAPK	12365.155	uM	0.37142	0.34986	0.1277	0.0144	0.4900	0.3947	0.9904	2.1113
MCF12A	NM	Basal B	Selumetinib		MEK	MAPK	10817.155	uM	0.24901	0.37316	-0.0670	-0.1302	0.5722	0.4400	0.9975	1.6045
MCF12A	NM	Basal B	Sigma A6730		AKT	AKT	10817.153	uM	9.26280	32.58580	-0.3416	-1.0000	0.8734	0.2269	0.9801	1.6726
MCF12A	NM	Basal B	Sigma A6730		AKT	AKT	12365.165	uM	13.69190	22.9060	-0.8300	-1.0000	2.1349	0.1831	0.9923	1.9114
MCF12A	NM	Basal B	Sirolimus		MTOR	MTOR	7489.068	uM	175.90010	143.66990	0.4631	0.0155	0.1561	0.2850	0.8468	2.0392
MCF12A	NM	Basal B	Sirolimus		MTOR	MTOR	7491.068	uM	0.00171	0.00210	-0.2455	-0.0728	0.6618	0.8885	0.8990	0.5270
MCF12A	NM	Basal B	Sorafenib		PDGFR/VEGFR/KIT/FLT3	RTK	7489.084	uM	19.81470	42.22190	-0.8904	-0.9576	1.4142	0.4793	0.9961	2.0279
MCF12A	NM	Basal B	Sorafenib		PDGFR/VEGFR/KIT/FLT3	RTK	7490.085	uM	39.92090	57.6870	-0.7001	-0.7241	2.4321	0.2465	0.9980	2.5778
MCF12A	NM	Basal B	Sunitinib		PDGFR/VEGFR/KIT/FLT3	RTK	7489.067	uM	6.85740	10.08440	-0.9372	-0.9320	2.7284	0.3781	0.9972	1.7603
MCF12A	NM	Basal B	Sunitinib		PDGFR/VEGFR/KIT/FLT3	RTK	7490.067	uM	7.63710	11.76840	-0.7152	-0.7251	2.0726	0.3536	0.9981	2.6472
MCF12A	NM	Basal B	TAPI-0		TACE/Collagenase		7490.096	uM	inf	3.02970	0.8804	0.8800	2.7946	0.0333	0.7938	2.5767
MCF12A	NM	Basal B	Taxol		TUBB	TUBB	10061.002	uM	0.02796	0.01249	0.1491	0.3357	1.3814	0.3870	0.9179	1.8759
MCF12A	NM	Basal B	Taxol		TUBB	TUBB	12949.002	uM	0.01123	0.01112	0.0260	0.0246	5.0000	0.6077	0.9919	1.7484
MCF12A	NM	Basal B	Taxol		TUBB	TUBB	7873.002	uM	0.01098	0.01109	-0.0795	-0.0264	5.0000	0.6250	0.9932	2.0331

|<
<<
Previous
Page 210 of 370
Next
>>
>
5226 to 5250 of 9248 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)